21 March 2017Pharma

Video interview: Taylor Wessing on SPCs at the CJEU

There have been two significant references on issues that have been "left hanging" by the Court of Justice of the European Union (CJEU) in the last spate of decisions, says Paul England, senior associate at Taylor Wessing, in a video interview with LSIPR.  England discusses the two important references to the CJEU with regard to supplementary protection certificates.  Here he covers the Teva v Gilead Sciences and Abraxis Bioscience references, and talks about the importance of these cases.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Pharma
28 September 2026   Can a drug’s ‘inactive’ precursor qualify for a multi-million pound patent extension? The UK High Court has just delivered a ruling on Takeda's ADHD drug Elvanse, weighing regulatory precedent against a conflicting German decision.
Pharma
25 September 2026   Another Wegovy patent has been drawn into the long-running dispute between Mylan and Novo Nordisk over proposed generic versions of the weight-loss drug.
Pharma
24 September 2026   An Entresto Orange Book listing has survived a challenge in the US, while two trademark disputes handed Novartis contrasting fortunes at a European court.